Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 4/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195730 | 1.00 | MAPT (0.45) | MAPTTDP1ALDH1A1MAPK1KDM4E | |
| SCHEMBL27312276 | 0.86 | ALDH1A1 (0.41) | MAPTTDP1ALDH1A1MAPK1KDM4E | |
| SCHEMBL1708879 | 0.85 | ALDH1A1 (0.47) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL16950829 | 0.82 | ALDH1A1 (0.39) | MAPTALDH1A1TSHRNOTUMNPC1 | |
| SCHEMBL4487891 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MAPK1KDM4EHPGDHSD17B10 | |
| SCHEMBL39857 | 0.81 | ALDH1A1 (0.55) | MAPTTDP1ALDH1A1MAPK1KDM4E | |
| SCHEMBL26657030 | 0.81 | HPGDS (0.43) | MAPTTDP1ALDH1A1KDM4EHPGD | |
| SCHEMBL9265800 | 0.80 | AKR1C3 (0.45) | MAPTALDH1A1 | |
| SCHEMBL20436373 | 0.80 | ALDH1A1 (0.41) | MAPTTDP1ALDH1A1KDM4EHPGD | |
| SCHEMBL17077586 | 0.80 | TSHR (0.53) | MAPTTDP1ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | MAPT 3058/4885TDP1 1999/4885ALDH1A1 203/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | MAPT 2409/4885TDP1 1930/4885ALDH1A1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.